Aug 2026· Science Advances· Vol 12· 0 citations· 63 references
Medicine
TL;DR
This study provides evidence that in glucose intoxication contexts, skeletal muscle-derived lactate acts as the signal to provide negative feedback for hepatic gluconeogenesis, which induces skeletal muscle H3K18la acting as a negative regulator of IL-6 to sustain suppression of hepatic gluconeogenesis, while dysregulation of this network contributes to unrestrained gluconeogenesis in diabetes.
Abstract
The mechanisms underlying the dynamic interplay between skeletal muscle and systemic glucose homeostasis in type 2 diabetes remain elusive. Increased lactate level has long been noticed in diabetes, however, whether the elevated lactate is a cause or consequence of impaired glucose metabolism is unclear. Here, we found that elevated circulating lactate levels originated from skeletal muscle with high expression of lactate dehydrogenase A (Ldha), and both metrics correlated strongly with hyperglycemia in both hyperglycemic mouse models and human subjects. Paradoxically, ablation of Ldha in skeletal muscle (LDHA mKO) disrupted whole-body glucose homeostasis, primarily via augmented hepatic gluconeogenesis. Mechanistically, lactate deficiency in muscle epigenetically activated NF-κB signaling through H3K18 lactylation (H3K18la)-mediated transcriptional control of IκBα, which then promoted the transcription of IL-6, thereby reshaping hepatic gluconeogenesis. Lastly, we showed that loss of Ldha in skeletal muscle enhanced hepatic gluconeogenesis and aggravated hyperglycemia in high-fat high-sucrose diet-fed mice. Collectively, our study provides evidence that in glucose intoxication contexts, skeletal muscle-derived lactate acts as the signal to provide negative feedback for hepatic gluconeogenesis, which induces skeletal muscle H3K18la acting as a negative regulator of IL-6 to sustain suppression of hepatic gluconeogenesis, while dysregulation of this network contributes to unrestrained gluconeogenesis in diabetes.
The results establish PDIA5 as a critical molecular checkpoint linking hepatic lipid overload to glucose dysregulation, and highlight it as a potential therapeutic target for type 2 diabetes.
Jin-Tao Wan, Ming-Liang Zhang, Teng Ma et al.· Diabetologia· 0 citations
AIMS
This study investigated the impact of hyperglycemia on systemic and skeletal muscle metabolite profiles.
METHODS
Serum and gastrocnemius metabolites of fructose-fed, streptozotocin-injected rats (T2D) were analyzed by 1H NMR and related to markers of energy metabolism and mitochondrial remodeling.
RESULTS
T2D...
Alexandra Moreira-Pais, Filipe Oliveira-Brás, Rúben J. Moreira et al.· Journal of diabetes and its...· 0 citations
Abstract Context Insulin deficiency (ID) causes severe metabolic defects and death if untreated, while insulin therapy does not fully restore metabolic homeostasis. Leptin therapy corrects metabolic abnormalities and promotes survival in rodents unable to produce insulin, suggesting the existence of insulin-independent...
Pryscila D. S. Teixeira, S. Vincent, Romane Meurs et al.· Endocrinology· 0 citations
Trimethylamine N-oxide (TMAO), a gut microbiota-derived metabolite, promotes cardiac hypertrophy, yet the molecular mechanisms linking microbial metabolism to cardiac gene expression remain incompletely defined. Ketohexokinase (KHK), the rate-limiting enzyme of fructose catabolism, is implicated in cardiac pathology, b...
Hepatic insulin resistance and fat accumulation are common features of metabolic syndrome, obesity and type 2 diabetes (T2D). However, whether the copper importer SLC31A1 has a role in diabetes-associated hepatic metabolic disorders remains unknown. Thus, we studied the role of hepatocyte SLC31A1 in HFD/STZ-induced T2D...
Yin-Qin Cheng, Min Wei, Le Yang et al.· Biochemistry and Biophysics...· 0 citations
The escalating global burden of metabolic diseases including obesity, type 2 diabetes, and metabolic dysfunction-associated fatty liver disease (MAFLD)-highlights an urgent need to identify new therapeutic targets. Although elevated hepatic de novo lipogenesis (DNL) is a hallmark of metabolic dysfunction, targeting i...
Wei Wang, Hui Wang, Yi-Han Liu et al.· Cell Death Discovery· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.